DE60224200T2 - Assayverfahren für alzheimer-krankheit - Google Patents

Assayverfahren für alzheimer-krankheit Download PDF

Info

Publication number
DE60224200T2
DE60224200T2 DE60224200T DE60224200T DE60224200T2 DE 60224200 T2 DE60224200 T2 DE 60224200T2 DE 60224200 T DE60224200 T DE 60224200T DE 60224200 T DE60224200 T DE 60224200T DE 60224200 T2 DE60224200 T2 DE 60224200T2
Authority
DE
Germany
Prior art keywords
antibody
xaa
seq
subject
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224200T
Other languages
German (de)
English (en)
Other versions
DE60224200D1 (de
Inventor
Ronald St. Louis DEMATTOS
Kelly R. Cloverdale BALES
David J. Indianapolis CUMMINS
Steven M. Carmel PAUL
David M. Holtzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Eli Lilly and Co
Washington University in St. Louis
Original Assignee
University of Washington
Eli Lilly and Co
Washington University in St. Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Eli Lilly and Co, Washington University in St. Louis filed Critical University of Washington
Application granted granted Critical
Publication of DE60224200D1 publication Critical patent/DE60224200D1/de
Publication of DE60224200T2 publication Critical patent/DE60224200T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60224200T 2001-08-17 2002-08-16 Assayverfahren für alzheimer-krankheit Expired - Lifetime DE60224200T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31322401P 2001-08-17 2001-08-17
US31322101P 2001-08-17 2001-08-17
US313221P 2001-08-17
US313224P 2001-08-17
US33498701P 2001-10-23 2001-10-23
US334987P 2001-10-23
PCT/US2002/026321 WO2003015617A2 (en) 2001-08-17 2002-08-16 Assay method for alzheimer's disease

Publications (2)

Publication Number Publication Date
DE60224200D1 DE60224200D1 (de) 2008-01-31
DE60224200T2 true DE60224200T2 (de) 2008-07-10

Family

ID=27405654

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224200T Expired - Lifetime DE60224200T2 (de) 2001-08-17 2002-08-16 Assayverfahren für alzheimer-krankheit

Country Status (10)

Country Link
EP (1) EP1416965B8 (enExample)
JP (2) JP4511830B2 (enExample)
AT (1) ATE381346T1 (enExample)
CA (1) CA2457145C (enExample)
CY (1) CY1107901T1 (enExample)
DE (1) DE60224200T2 (enExample)
DK (1) DK1416965T3 (enExample)
ES (1) ES2295401T3 (enExample)
PT (1) PT1416965E (enExample)
WO (1) WO2003015617A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
EP1944040B1 (en) 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008088983A1 (en) 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5704533B2 (ja) * 2009-02-13 2015-04-22 国立大学法人大阪大学 アルツハイマー病の診断方法および診断薬
EP2510359B1 (en) 2009-12-11 2015-09-02 Araclón Biotech, S. L. Methods and reagents for improved detection of amyloid beta peptides
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
KR102496845B1 (ko) * 2018-08-08 2023-02-08 서울대학교산학협력단 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010569A1 (en) * 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6730778B2 (en) * 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
EA006606B1 (ru) * 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения

Also Published As

Publication number Publication date
PT1416965E (pt) 2008-04-01
EP1416965B8 (en) 2008-02-13
WO2003015617A3 (en) 2004-01-29
DK1416965T3 (da) 2008-05-05
CY1107901T1 (el) 2013-09-04
JP2004538477A (ja) 2004-12-24
EP1416965A2 (en) 2004-05-12
CA2457145C (en) 2010-12-21
ES2295401T3 (es) 2008-04-16
ATE381346T1 (de) 2008-01-15
JP5162553B2 (ja) 2013-03-13
EP1416965B1 (en) 2007-12-19
HK1061960A1 (en) 2004-10-15
WO2003015617A2 (en) 2003-02-27
JP4511830B2 (ja) 2010-07-28
DE60224200D1 (de) 2008-01-31
CA2457145A1 (en) 2003-02-27
JP2010044078A (ja) 2010-02-25
EP1416965A4 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
DE60106394T2 (de) Humanisierte antikörper, die amyloid beta peptid sequestrieren
DE60226036T3 (de) ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
US7771722B2 (en) Assay method for alzheimer's disease
JP5162553B2 (ja) アルツハイマー病のアッセイ方法
KR101713365B1 (ko) 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
AU2002329775A1 (en) Assay method for alzheimer's disease
DE69126607T2 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
HUE033466T2 (en) Humanized antibody to beta-amyloid
EP3424527A1 (de) Diagnostisches verfahren
DE69813181T2 (de) Icam-4 und dessen diagnostische verwendungen
KR20160127133A (ko) 섬 아밀로이드 폴리펩티드(iapp) 유도된 베타-세포 부상 및 손상된 글루코오스 내성을 길항할 수 있는 신규한 화합물
HK1061960B (en) Assay method for alzheimer's disease
HK1186243B (en) Safe and functional humanized antibodies for use in treating an amyloidosis
HK1186243A (en) Safe and functional humanized antibodies for use in treating an amyloidosis

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: BALES, KELLY R., CLOVERDALE, IN 46120, US

Inventor name: CUMMINS, DAVID J., INDIANAPOLIS, IN 46256, US

Inventor name: PAUL, STEVEN M., CARMEL, IN 46032, US

Inventor name: HOLTZMANN, DAVID M., ST. LOUIS, MO, US

Inventor name: DEMATTOS, RONALD, ST. LOUIS, MO 63108, US

8364 No opposition during term of opposition